Regeneron to Participate in H.C. Wainwright & Co. Virtual Event

Rhea-AI Summary

Regeneron Pharmaceuticals (NASDAQ: REGN) will participate in a virtual fireside chat at the H.C. Wainwright & Co. event on December 6, 2021, at 2:00 p.m. ET. Aris Baras, M.D., Senior Vice President and Head of the Regeneron Genetics Center, will represent the company. The session can be accessed via Regeneron's 'Investors & Media' page and will be archived for replay for at least 30 days. Regeneron is known for its transformative medicines, with nine FDA-approved treatments, focusing on serious diseases.

TARRYTOWN, N.Y., Dec. 3, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is scheduled to participate in a virtual fireside chat at the H.C. Wainwright & Co. event – Unlocking the Full Potential of RNAi With World-Class Novel Target Identification: Regeneron Genomics and Alnylam's RNAi Platform Collaboration Update – at 2:00 p.m. ET on Monday, December 6, 2021.

Aris Baras, M.D., Senior Vice President at Regeneron and Head of the Regeneron Genetics Center, will participate on behalf of Regeneron.

The session may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. A replay of the webcast will be archived on the Company's website for at least 30 days.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite^® technologies, such as VelocImmune^®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information:
Investor Relations                                             
Mark Hudson                                                             
914.847.3482                                                    
mark.hudson@regeneron.com

View original content:https://www.prnewswire.com/news-releases/regeneron-to-participate-in-hc-wainwright--co-virtual-event-301437162.html

SOURCE Regeneron Pharmaceuticals, Inc.

FAQ

What is Regeneron participating in on December 6, 2021?

Regeneron is participating in a virtual fireside chat at the H.C. Wainwright & Co. event.

Who will represent Regeneron in the H.C. Wainwright virtual event?

Aris Baras, M.D., Senior Vice President and Head of the Regeneron Genetics Center, will represent Regeneron.

Where can I watch the Regeneron virtual fireside chat?

The session can be accessed via the 'Investors & Media' page of Regeneron's website.

How long will the Regeneron event webcast be available for replay?

The webcast will be archived for at least 30 days.

What is Regeneron's focus in its drug development?

Regeneron focuses on inventing life-transforming medicines for serious diseases, including those affecting the eyes, allergies, cancer, and rare diseases.